PuSH - Publikationsserver des Helmholtz Zentrums München

Nakamura, A.* ; Wong, Y.F.* ; Venturato, A.* ; Michaut, M.* ; Venkateswaran, S.* ; Santra, M.* ; Gonçalves, C.* ; Larsen, M.* ; Leuschner, M.* ; Kim, Y.H.* ; Brickman, J.* ; Bradley, M.* ; Grapin-Botton, A.

Long-term feeder-free culture of human pancreatic progenitors on fibronectin or matrix-free polymer potentiates β cell differentiation.

Stem Cell Rep. 17, 1215-1228 (2022)
Verlagsversion Forschungsdaten DOI
Open Access Gold
Creative Commons Lizenzvertrag
With the aim of producing β cells for replacement therapies to treat diabetes, several protocols have been developed to differentiate human pluripotent stem cells to β cells via pancreatic progenitors. While in vivo pancreatic progenitors expand throughout development, the in vitro protocols have been designed to make these cells progress as fast as possible to β cells. Here, we report on a protocol enabling a long-term expansion of human pancreatic progenitors in a defined medium on fibronectin, in the absence of feeder layers. Moreover, through a screening of a polymer library we identify a polymer that can replace fibronectin. Our experiments, comparing expanded progenitors to directly differentiated progenitors, show that the expanded progenitors differentiate more efficiently into glucose-responsive β cells and produce fewer glucagon-expressing cells. The ability to expand progenitors under defined conditions and cryopreserve them will provide flexibility in research and therapeutic production.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Beta Cells ; Differentiation ; Endocrine Cells ; Human ; Long-term Culture ; Pancreas ; Pancreatic Progenitors ; Screening ; Transcriptome
ISSN (print) / ISBN 2213-6711
Zeitschrift Stem Cell Reports
Quellenangaben Band: 17, Heft: 5, Seiten: 1215-1228 Artikelnummer: , Supplement: ,
Verlag Cell Press
Verlagsort Maryland Heights, MO
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Pancreatic Beta Cell Research (IPI)
Förderungen Novo Nordisk Foundation, Denmark grant
Novo Nordisk Foundation